The Role of IDO in Muc1 Targeted Immunotherapy
Annual summary rept. 1 Jan 2011-30 Jun 2013
NORTH CAROLINA UNIV AT CHARLOTTE
Pagination or Media Count:
While many advancements have been made in breast cancer therapy, metastatic breast cancer remains an incurable disease. MUC1 is a glycoprotein expressed on normal glandular epithelial but is over-expressed and underglycosylated in over 90 of human breast tumors and metastatic lesions, which lead to its ranking by NCI as the second most targetable antigen. To this end, we have proposed vaccinating with peptides from the MUC1 protein core, which is only visible to the immune system on the tumor-associated form of the protein. Previous work from our lab has demonstrated that this vaccine does elicit a MUC1-specific immune response that can only be functional if the immunosuppressive tumor microenvironment is altered to allow efficient killing of tumor cells. Thus, we investigated the effectiveness of MUC1 vaccination in combination with drugs known to inhibit immunosuppression to determine which drug is the most effective. Mice that are transgenic for human MUC1 MUC1.Tg mice were orthotopically injected with a syngenic breast cancer cell line expressing human MUC1 Mtag.MUC1. Mice were vaccinated after palpable tumor formation three times at a 10 day interval with the vaccine cocktail, consisting of two MHC class I-restricted MUC1 tandem repeat peptides and a class II pan helper peptide mixed with GM-CSF and CpG ODN, in incomplete Freund s adjuvant. Previous work in our lab has shown that blocking the cyclooxygenase pathway COX resulted in an inhibition of immunosuppression. Thus we used the following drugs in combination with the MUC1- vaccine therapy Indomethacine COX1 and COX2 inhibitor, Celecoxib COX2 inhibitor, 1-methyl tryptophan indoleamine 2,3 dioxygenase inihibitor, and AH6809 EP2 receptor antagonist. Mice were euthanized and tissue was collected 2 days post the final vaccination.
- Medicine and Medical Research